Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

A core outcome set for studies of gestational diabetes mellitus prevention and treatment.

Egan AM, Bogdanet D, Griffin TP, Kgosidialwa O, Cervar-Zivkovic M, Dempsey E, Allotey J, Alvarado F, Clarson C, Cooray SD, de Valk HW, Galjaard S, Loeken MR, Maresh MJA, Napoli A, O'Shea PM, Wender-Ozegowska E, van Poppel MNM, Thangaratinam S, Crowther C, Biesty LM, Devane D, Dunne FP; INSPIRED research group.

Diabetologia. 2020 Mar 20. doi: 10.1007/s00125-020-05123-6. [Epub ahead of print]

PMID:
32193573
2.

High prevalence of impaired awareness of hypoglycemia and severe hypoglycemia among people with insulin-treated type 2 diabetes: The Dutch Diabetes Pearl Cohort.

van Meijel LA, de Vegt F, Abbink EJ, Rutters F, Schram MT, van der Klauw MM, Wolffenbuttel BHR, Siegelaar S, DeVries JH, Sijbrands EJG, Özcan B, de Valk HW, Silvius B, Schaper N, Stehouwer CDA, Elders PJM, Tack CJ, de Galan BE.

BMJ Open Diabetes Res Care. 2020 Feb;8(1). pii: e000935. doi: 10.1136/bmjdrc-2019-000935.

3.

Normal-range thyroid-stimulating hormone levels and cardiovascular events and mortality in type 2 diabetes.

de Vries TI, de Valk HW, van der Graaf Y, de Borst GJ, Cramer MJM, Jaap Kappelle L, Visseren FLJ, Westerink J; SMART study group.

Diabetes Res Clin Pract. 2019 Nov;157:107880. doi: 10.1016/j.diabres.2019.107880. Epub 2019 Oct 16.

PMID:
31628967
4.

Apparent therapy-resistant hypertension as risk factor for the development of type 2 diabetes mellitus.

Holtrop J, Spiering W, Nathoe HM, De Borst GJ, Kappelle LJ, De Valk HW, Visseren FLJ, Westerink J; SMART Study Group.

J Hypertens. 2020 Jan;38(1):45-51. doi: 10.1097/HJH.0000000000002227.

PMID:
31568056
5.

[Insulin pump regulated by a glucose sensor; one step closer to closing the loop for type 1 diabetes patients].

de Valk HW.

Ned Tijdschr Geneeskd. 2019 Sep 24;163. pii: D3713. Dutch.

PMID:
31556504
6.

SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial.

de Wit L, Rademaker D, Voormolen DN, Akerboom BMC, Kiewiet-Kemper RM, Soeters MR, Verwij-Didden MAL, Assouiki F, Schippers DH, Vermeulen MAR, Kuppens SMI, Oosterwerff MM, Zwart JJ, Diekman MJM, Vogelvang TE, Gallas PRJ, Galjaard S, Visser W, Horree N, Klooker TK, Laan R, Heijligenberg R, Huisjes AJM, van Bemmel T, van Meir CA, van den Beld AW, Hermes W, Vidarsdottir S, Veldhuis-Vlug AG, Dullemond RC, Jansen HJ, Sueters M, de Koning EJP, van Laar JOEH, Wouters-van Poppel P, Sanson-van Praag ME, van den Akker ES, Brouwer CB, Hermsen BB, Potter van Loon BJ, van der Heijden OWH, de Galan BE, van Leeuwen M, Wijbenga JAM, de Boer K, van Bon AC, van der Made FW, Eskes SA, Zandstra M, van Houtum WH, Braams-Lisman BAM, Daemen-Gubbels CRGM, Wouters MGAJ, IJzerman RG, Mensing van Charante NA, Zwertbroek R, Bosmans JE, Evers IM, Mol BW, de Valk HW, Groenendaal F, Naaktgeboren CA, Painter RC, deVries JH, Franx A, van Rijn BB.

BMJ Open. 2019 Aug 18;9(8):e029808. doi: 10.1136/bmjopen-2019-029808.

7.

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.

Fadini GP, Feher M, Hansen TK, de Valk HW, Koefoed MM, Wolden M, Zimmermann E, Jendle J.

J Clin Endocrinol Metab. 2019 Dec 1;104(12):5977-5990. doi: 10.1210/jc.2019-01021.

8.

Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey.

Bogdanet D, Reddin C, Macken E, Griffin TP, Fhelelboom N, Biesty L, Thangaratinam S, Dempsey E, Crowther C, Galjaard S, Maresh M, Loeken MR, Napoli A, Anastasiou E, Noctor E, de Valk HW, van Poppel MNM, Agostini A, Clarson C, Egan AM, O'Shea PM, Devane D, Dunne FP.

Diabetologia. 2019 Nov;62(11):2007-2016. doi: 10.1007/s00125-019-4935-9. Epub 2019 Jul 4.

9.

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.

Bosi E, Choudhary P, de Valk HW, Lablanche S, Castañeda J, de Portu S, Da Silva J, Ré R, Vorrink-de Groot L, Shin J, Kaufman FR, Cohen O; SMILE Study Group.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):462-472. doi: 10.1016/S2213-8587(19)30150-0. Epub 2019 Apr 29.

PMID:
31047902
10.

Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands.

Roze S, Smith-Palmer J, de Portu S, Delbaere A, de Brouwer B, de Valk HW.

Clinicoecon Outcomes Res. 2019 Jan 14;11:73-82. doi: 10.2147/CEOR.S186298. eCollection 2019.

11.

Study of MiniMed 640G Insulin Pump with SmartGuard in Prevention of Low Glucose Events in Adults with Type 1 Diabetes (SMILE): Design of a Hypoglycemia Prevention Trial with Continuous Glucose Monitoring Data as Outcomes.

De Valk HW, Lablanche S, Bosi E, Choudhary P, Silva JD, Castaneda J, Vorrink L, De Portu S, Cohen O.

Diabetes Technol Ther. 2018 Nov;20(11):758-766. doi: 10.1089/dia.2018.0222. Epub 2018 Oct 16.

PMID:
30325656
12.

Thyroid-stimulating hormone levels in the normal range and incident type 2 diabetes mellitus.

de Vries TI, Kappelle LJ, van der Graaf Y, de Valk HW, de Borst GJ, Nathoe HM, Visseren FLJ, Westerink J; SMART study group.

Acta Diabetol. 2019 Apr;56(4):431-440. doi: 10.1007/s00592-018-1231-y. Epub 2018 Sep 27.

13.

High Diabetes Distress Among Ethnic Minorities Is Not Explained by Metabolic, Cardiovascular, or Lifestyle Factors: Findings From the Dutch Diabetes Pearl Cohort.

Özcan B, Rutters F, Snoek FJ, Roosendaal M, Sijbrands EJ, Elders PJM, Holleman F, Pijl H, Tack CJ, Abbink EJ, de Valk HW, Wolffenbuttel BHR, Stehouwer CDA, Schaper NC, Dekker JM, Schram MT; Diabetes Pearl from the Parelsnoer Initiative.

Diabetes Care. 2018 Sep;41(9):1854-1861. doi: 10.2337/dc17-2181. Epub 2018 Jun 26.

PMID:
29945936
14.

Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial.

Voormolen DN, DeVries JH, Sanson RME, Heringa MP, de Valk HW, Kok M, van Loon AJ, Hoogenberg K, Bekedam DJ, Brouwer TCB, Porath M, Erdtsieck RJ, NijBijvank B, Kip H, van der Heijden OWH, Elving LD, Hermsen BB, Potter van Loon BJ, Rijnders RJP, Jansen HJ, Langenveld J, Akerboom BMC, Kiewiet RM, Naaktgeboren CA, Mol BWJ, Franx A, Evers IM.

Diabetes Obes Metab. 2018 Aug;20(8):1894-1902. doi: 10.1111/dom.13310. Epub 2018 May 8.

PMID:
29603547
15.

Long-term BMI and growth profiles in offspring of women with gestational diabetes.

Hammoud NM, Visser GHA, van Rossem L, Biesma DH, Wit JM, de Valk HW.

Diabetologia. 2018 May;61(5):1037-1045. doi: 10.1007/s00125-018-4584-4. Epub 2018 Feb 28.

16.

Individual and partner's level of occupation and the association with HbA1c levels in people with Type 2 diabetes mellitus: the Dutch Diabetes Pearl cohort.

Rutte A, Rauh SP, Schram MT, Nijpels G, DeVries JH, Holleman F, Pijl H, Dekkers OM, Özcan B, Sijbrands EJG, Tack CJ, Abbink EJ, de Valk HW, Silvius B, Wolffenbuttel BHR, Stehouwer CDA, Schaper NC, Dekker JM, Beulens JW, Elders PJM, Rutters F; Diabetes Pearl from the Parelsnoer Initiative.

Diabet Med. 2017 Nov;34(11):1623-1628. doi: 10.1111/dme.13422. Epub 2017 Aug 3.

PMID:
28703888
17.

A core outcome set for studies evaluating the effectiveness of prepregnancy care for women with pregestational diabetes.

Egan AM, Galjaard S, Maresh MJA, Loeken MR, Napoli A, Anastasiou E, Noctor E, de Valk HW, van Poppel M, Todd M, Smith V, Devane D, Dunne FP.

Diabetologia. 2017 Jul;60(7):1190-1196. doi: 10.1007/s00125-017-4277-4. Epub 2017 Apr 13.

18.

[A diabetic patient with blisters].

Donkers CM, van Welzen BJ, de Valk HW.

Ned Tijdschr Geneeskd. 2017;161:D838. Dutch.

PMID:
28224870
19.

Growth and BMI during the first 14 y of life in offspring from women with type 1 or type 2 diabetes mellitus.

Hammoud NM, de Valk HW, van Rossem L, Biesma DH, Wit JM, Visser GH.

Pediatr Res. 2017 Feb;81(2):342-348. doi: 10.1038/pr.2016.236. Epub 2016 Nov 9.

PMID:
27828938
20.

Effect modification in the association between glycated haemoglobin and cardiovascular disease and mortality in patients with type 2 diabetes.

van Munster SN, van der Graaf Y, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Obes Metab. 2017 Mar;19(3):320-328. doi: 10.1111/dom.12820. Epub 2016 Dec 28.

PMID:
27807924
21.

Intrauterine Adiposity and BMI in 4- to 5-Year-Old Offspring from Diabetic Pregnancies.

Hammoud NM, de Valk HW, Biesma DH, Visser GH.

Neonatology. 2017;111(2):177-181. doi: 10.1159/000448681. Epub 2016 Oct 28.

22.

Response to Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424-1430.

Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Care. 2016 Oct;39(10):e190-1. doi: 10.2337/dci16-0023. No abstract available.

PMID:
27660133
23.

Maturity onset diabetes of the young: Seek and you will find.

Heuvel-Borsboom H, de Valk HW, Losekoot M, Westerink J.

Neth J Med. 2016 Jun;74(5):193-200. Review.

24.

Cystic Fibrosis-Related Diabetes with strict glycaemic control is not associated with frequent intravenous antibiotics use for pulmonary infections.

Belle-van Meerkerk G, de Valk HW, Stam-Slob MC, Teding van Berkhout F, Zanen P, van de Graaf EA.

Diabetes Res Clin Pract. 2016 Jun;116:230-6. doi: 10.1016/j.diabres.2016.04.014. Epub 2016 Apr 27.

PMID:
27321340
25.

HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes.

Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J; SMART Study Group.

Diabetes Care. 2016 Aug;39(8):1424-30. doi: 10.2337/dc16-0155. Epub 2016 May 23.

PMID:
27222511
26.

Association between vascular health and ovarian ageing in type 1 diabetes mellitus.

Yarde F, Spiering W, Franx A, Visseren FL, Eijkemans MJ, de Valk HW, Broekmans FJ; OVADIA Study Group.

Hum Reprod. 2016 Jun;31(6):1354-62. doi: 10.1093/humrep/dew063. Epub 2016 Apr 6.

PMID:
27052503
27.

Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.

Roze S, Duteil E, Smith-Palmer J, de Portu S, Valentine W, de Brouwer BF, Reznik Y, de Valk HW.

J Med Econ. 2016 Aug;19(8):742-9. doi: 10.3111/13696998.2016.1167695. Epub 2016 Apr 5.

PMID:
26985982
28.

Pretransplant HRCT Characteristics Are Associated with Worse Outcome of Lung Transplantation for Cystic Fibrosis Patients.

Belle-van Meerkerk G, de Jong PA, de Valk HW, Neefjes T, Pameijer FA, Kwakkel-van Erp JM, van de Graaf EA.

PLoS One. 2015 Dec 23;10(12):e0145597. doi: 10.1371/journal.pone.0145597. eCollection 2015.

29.

A patient with severe haemophilia A and multiple arterial thromboses caused by large vessel vasculitis: a case report.

Vos LM, Schutgens RE, de Valk HW, Spiering W, Bemelmans RH.

Haemophilia. 2016 Jan;22(1):e39-42. doi: 10.1111/hae.12787. Epub 2015 Nov 17. No abstract available.

PMID:
26572080
30.

Age at menopause in women with type 1 diabetes mellitus: the OVADIA study.

Yarde F, van der Schouw YT, de Valk HW, Franx A, Eijkemans MJ, Spiering W, Broekmans FJ; OVADIA study group.

Hum Reprod. 2015 Feb;30(2):441-6. doi: 10.1093/humrep/deu327. Epub 2014 Dec 1.

PMID:
25452435
31.

Management of diabetes in pregnancy: antenatal follow-up and decisions concerning timing and mode of delivery.

Visser GH, de Valk HW.

Best Pract Res Clin Obstet Gynaecol. 2015 Feb;29(2):237-43. doi: 10.1016/j.bpobgyn.2014.08.005. Epub 2014 Aug 21. Review.

PMID:
25205235
32.

Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin.

de Ranitz-Greven WL, Beulens JW, Hoeks LB, Belle-van Meerkerk G, Biesma DH, de Valk HW.

BMC Res Notes. 2014 Aug 29;7:579. doi: 10.1186/1756-0500-7-579.

33.

Similar adverse pregnancy outcome in native and nonnative dutch women with pregestational type 2 diabetes: a multicentre retrospective study.

Groen B, Links TP, van den Berg PP, Hellinga M, Moerman S, Visser GH, Sluiter WJ, Faas MM, Schreuder MC, Visser W, Geelhoed-Duijvestijn PH, Bianchi R, Bartelink AK, de Valk HW.

ISRN Obstet Gynecol. 2013 Oct 30;2013:361435. doi: 10.1155/2013/361435. eCollection 2013.

34.

New-onset saquinavir-induced diabetes.

van Zoelen MA, Hoepelman AI, de Valk HW.

Diabetes Care. 2013 Dec;36(12):e199. doi: 10.2337/dc13-1645. No abstract available.

35.

Reply: To PMID 23103371.

Visser GH, de Valk HW.

Am J Obstet Gynecol. 2014 Mar;210(3):281-2. doi: 10.1016/j.ajog.2013.09.008. Epub 2013 Sep 10. No abstract available.

PMID:
24035983
36.

Phenylketonuria: reduced tyrosine brain influx relates to reduced cerebral protein synthesis.

de Groot MJ, Hoeksma M, Reijngoud DJ, de Valk HW, Paans AM, Sauer PJ, van Spronsen FJ.

Orphanet J Rare Dis. 2013 Sep 4;8:133. doi: 10.1186/1750-1172-8-133.

37.

Pulmonary hypertension is a mild comorbidity in end-stage cystic fibrosis patients.

Belle-van Meerkerk G, Cramer MJ, Kwakkel-van Erp JM, Nugroho MA, Tahri S, de Valk HW, van de Graaf EA.

J Heart Lung Transplant. 2013 Jun;32(6):609-14. doi: 10.1016/j.healun.2013.03.006. Epub 2013 Apr 9.

PMID:
23582476
38.

The prevalence of diabetes mellitus is increased in relatives of patients with a non-affective psychotic disorder.

van Welie H, Derks EM, Verweij KH, de Valk HW, Kahn RS, Cahn W.

Schizophr Res. 2013 Feb;143(2-3):354-7. doi: 10.1016/j.schres.2012.11.011. Epub 2012 Dec 12.

PMID:
23245702
39.

The Diabetes Pearl: Diabetes biobanking in The Netherlands.

van't Riet E, Schram MT, Abbink EJ, Admiraal WM, Dijk-Schaap MW, Holleman F, Nijpels G, Özcan B, Pijl H, Schaper NC, Sijbrands EJ, Silvius B, Tack CJ, de Valk HW, Wolffenbuttel BH, Stehouwer CD, Dekker JM.

BMC Public Health. 2012 Nov 6;12:949. doi: 10.1186/1471-2458-12-949.

40.

Advanced glycation end products, measured as skin autofluorescence, during normal pregnancy and pregnancy complicated by diabetes mellitus.

de Ranitz-Greven WL, Kaasenbrood L, Poucki WK, Hamerling J, Bos DC, Visser GH, Biesma DH, Beulens JW, de Valk HW.

Diabetes Technol Ther. 2012 Dec;14(12):1134-9. doi: 10.1089/dia.2012.0120. Epub 2012 Oct 31.

PMID:
23113747
41.

Is the evidence strong enough to change the diagnostic criteria for gestational diabetes now?

Visser GH, de Valk HW.

Am J Obstet Gynecol. 2013 Apr;208(4):260-4. doi: 10.1016/j.ajog.2012.10.881. Epub 2012 Oct 24.

PMID:
23103371
42.

Gestational diabetes mellitus diagnosed by screening or symptoms: does it matter?

Hammoud NM, de Valk HW, Biesma DH, Visser GH.

J Matern Fetal Neonatal Med. 2013 Jan;26(1):103-5. doi: 10.3109/14767058.2012.722718. Epub 2012 Sep 25.

PMID:
22937897
43.

Fetal growth profiles of macrosomic and non-macrosomic infants of women with pregestational or gestational diabetes.

Hammoud NM, Visser GH, Peters SA, Graatsma EM, Pistorius L, de Valk HW.

Ultrasound Obstet Gynecol. 2013 Apr;41(4):390-7. doi: 10.1002/uog.11221. Epub 2013 Mar 11.

44.

Diabetes before and after lung transplantation in patients with cystic fibrosis and other lung diseases.

Belle-van Meerkerk G, van de Graaf EA, Kwakkel-van Erp JM, van Kessel DA, Lammers JW, Biesma DH, de Valk HW.

Diabet Med. 2012 Aug;29(8):e159-62. doi: 10.1111/j.1464-5491.2012.03676.x.

PMID:
22486317
45.

Gestational diabetes: screening for all, which test and which treatment?

Visser GH, de Valk HW.

Expert Rev Endocrinol Metab. 2012 Mar;7(2):165-167. doi: 10.1586/eem.12.7.

PMID:
30764007
46.

Cardiac function in 7-8-year-old offspring of women with type 1 diabetes.

Rijpert M, Breur JM, Evers IM, de Valk HW, Heijnen CJ, Meijboom FJ, Visser GH.

Exp Diabetes Res. 2011;2011:564316. doi: 10.1155/2011/564316. Epub 2011 Nov 15.

47.

Advanced glycation end products, measured as skin autofluorescence, at diagnosis in gestational diabetes mellitus compared with normal pregnancy.

de Ranitz-Greven WL, Bos DC, Poucki WK, Visser GH, Beulens JW, Biesma DH, de Valk HW.

Diabetes Technol Ther. 2012 Jan;14(1):43-9. doi: 10.1089/dia.2011.0105. Epub 2011 Aug 29.

PMID:
21875328
48.

Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review.

Bos DC, de Ranitz-Greven WL, de Valk HW.

Diabetes Technol Ther. 2011 Jul;13(7):773-9. doi: 10.1089/dia.2011.0034. Epub 2011 Apr 21. Review.

PMID:
21510765
49.

Real-time continuous glucose monitoring system for treatment of diabetes: a systematic review.

Hoeks LB, Greven WL, de Valk HW.

Diabet Med. 2011 Apr;28(4):386-94. doi: 10.1111/j.1464-5491.2010.03177.x. Review.

PMID:
21392060
50.

[Gestational diabetes mellitus: treatment reduces the risk of complications].

van Leeuwen M, Prins SM, de Valk HW, Evers IM, Visser GH, Mol BW.

Ned Tijdschr Geneeskd. 2011;155:A2291. Review. Dutch.

PMID:
21382211

Supplemental Content

Loading ...
Support Center